Literature DB >> 7534477

Selectin ligands and tumor-associated carbohydrate structures: specificities of alpha 2,3-sialyltransferases in the assembly of 3'-sialyl-6-sialyl/sulfo Lewis a and x, 3'-sialyl-6'-sulfo Lewis x, and 3'-sialyl-6-sialyl/sulfo blood group T-hapten.

E V Chandrasekaran1, R K Jain, R D Larsen, K Wlasichuk, K L Matta.   

Abstract

The sequence in the assembly of the functional unit of selectin ligands containing sulfate, sialic acid, and fucose and also tumor-associated O-glycan structures was studied by examining the specificities of alpha 2,3-sialyltransferases (ST). The first enzyme, porcine liver ST, was 57, 37, and 79% active (Km: 0.105, 0.420, and 0.200 mM), respectively, toward 6-sulfo, 6-sialyl, or 6-O-methyl derivatives of the Gal beta 1,3GalNAc alpha- unit; C-3 or C-6 substitution on Gal abolished sialylation. An acrylamide copolymer (MW approximately 40,000) containing approximately 40 T-haptens and asialo Cowper's gland mucin (MW approximately 200,000) containing approximately 48 T-haptens was 5-fold more active as an acceptor as compared to Gal beta 1, 3GalNAc alpha-O-Al on a molecular weight basis. The second enzyme, a cloned alpha-2,3-ST specific for lactose-based structure, was 70, 102, and 108% active (Km: 0.500, 0.210, and 0.330 mM), respectively, toward 6-sialyl, 6-sulfo, or 6-O-methyl derivatives of the Gal beta 1,3GlcNAc beta- unit; C-3 and C-6 substitution on Gal abolished sialylation. Gal beta 1,4GlcNAc beta- and its 6-sulfo derivative were approximately 20% active; the Lewis a structure, Gal beta 1,3- (Fuc alpha 1,4)GlcNAc beta-, was not an acceptor. The acrylamide copolymers containing approximately 40 units of Gal beta 1,3GlcNAc beta-, Gal beta 1,3(6-sulfo)GlcNAc beta-, or fetuin triantennary asialo or bovine IgG diantennary glycopeptides were respectively 5.9-, 5.4-, 0.7-, and 0.1-fold as active. A transfer of 7-9 mol of NeuAc per mole of the above copolymers was catalyzed by this ST, the sialyl linkage being susceptible to alpha 2,3-specific sialidase. A partially purified Colo 205 Lewis type (alpha 1, 3/4) fucosyltransferase catalyzed the formation of 3'-sialyl-6-sulfo Lewis a from [9-3H]NeuAc alpha 2, 3Gal beta 1, 3(6-sulfo)GlcNAc beta-O-Allyl and copolymer containing [9-3H]NeuAc alpha 2, 3Gal beta 1, 3(6-sulfo)GlcNAc beta- units, using GDP[14C]Fuc as fucosyl donor. The third enzyme, HL-60 ST, was 103% active with Gal beta 3(6-sulfo)GalNAc alpha- but was only 8% active with 6-sialo compound; it showed 11.6-fold greater activity with the copolymer of T-hapten. Further, we observed the alpha 2,3 sialylation of Gal beta 1,4GlcNAc beta- but not Gal beta 1,3GlcNAc beta- by HL60-ST, consistent with the occurrence of 3'-sialyl LacNAc and 3'-sialyl Lewis x units in leukosialin of HL60.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534477     DOI: 10.1021/bi00009a024

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Synthesis of Gal-beta-(1-->4)-GlcNac-beta-(1-->6)-[Gal-beta-(1-->3]-GalNAc-alpha- OBn oligosaccharides bearing O-methyl or O-sulfo groups at C-3 of the Gal residue: specific acceptors for Gal: 3-O-sulfotransferases.

Authors:  R K Jain; C F Piskorz; E V Chandrasekaran; K L Matta
Journal:  Glycoconj J       Date:  1998-10       Impact factor: 2.916

2.  Reversible sialylation: synthesis of cytidine 5'-monophospho-N-acetylneuraminic acid from cytidine 5'-monophosphate with alpha2,3-sialyl O-glycan-, glycolipid-, and macromolecule-based donors yields diverse sialylated products.

Authors:  E V Chandrasekaran; Jun Xue; Jie Xia; Robert D Locke; Khushi L Matta; Sriram Neelamegham
Journal:  Biochemistry       Date:  2007-12-08       Impact factor: 3.162

Review 3.  Intervention of carbohydrate recognition by proteins and nucleic acids.

Authors:  P Sears; C H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  Characterization of a spleen sulphotransferase responsible for the 6-O-sulphation of the galactose residue in sialyl-N-acetyl-lactosamine sequences.

Authors:  R G Spiro; V D Bhoyroo
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

5.  Role for hepatic and circulatory ST6Gal-1 sialyltransferase in regulating myelopoiesis.

Authors:  Mark B Jones; Mehrab Nasirikenari; Li Feng; Marina T Migliore; Kyoung-Soo Choi; Latif Kazim; Joseph T Y Lau
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

6.  Circulating blood and platelets supply glycosyltransferases that enable extrinsic extracellular glycosylation.

Authors:  Melissa M Lee-Sundlov; David J Ashline; Andrew J Hanneman; Renata Grozovsky; Vernon N Reinhold; Karin M Hoffmeister; Joseph Ty Lau
Journal:  Glycobiology       Date:  2016-10-26       Impact factor: 4.313

7.  Characterization of distinct Gal:3-O-sulfotransferase activities in human tumor epithelial cell lines and of calf lymph node GlcNAc : 6-O-sulfotransferase activity.

Authors:  E V Chandrasekaran; R K Jain; J M Rhodes; R Chawda; C Piskorz; K L Matta
Journal:  Glycoconj J       Date:  1999-09       Impact factor: 2.916

Review 8.  The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors.

Authors:  Lokesh Dalasanur Nagaprashantha; Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sanjay Awasthi; Sharad S Singhal
Journal:  Int J Cancer       Date:  2010-12-07       Impact factor: 7.396

9.  Altered eosinophil profile in mice with ST6Gal-1 deficiency: an additional role for ST6Gal-1 generated by the P1 promoter in regulating allergic inflammation.

Authors:  Mehrab Nasirikenari; E V Chandrasekaran; Khushi L Matta; Brahm H Segal; Paul N Bogner; Amit A Lugade; Yasmin Thanavala; James J Lee; Joseph T Y Lau
Journal:  J Leukoc Biol       Date:  2009-12-09       Impact factor: 4.962

10.  Potential tumor markers for human gastric cancer: an elevation of glycan:sulfotransferases and a concomitant loss of alpha1,2-fucosyltransferase activities.

Authors:  E V Chandrasekaran; Jun Xue; Conrad Piskorz; Robert D Locke; Károly Tóth; Harry K Slocum; Khushi L Matta
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.